$IKT insider trading
Over the last 12 months, Inhibikase Therapeutics insiders reported 1 buy totaling $3.0M and 3 sales totaling — across SEC Form 4 filings.
- Bought · 12m
- $3.0M 1 event
- Sold · 12m
- — 3 events
- Events · 12m
- 4 Form 4 filings, grouped
- Insiders · 12m
- 4 distinct reporters
- 10b5-1 share
- 0% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Feb 21, 2026 | Aurentz VincentD | ▽ Sale to issuer | 255,299 | — | — | -33.3% | — |
| Feb 21, 2026 | Cabell ChristopherPresident & Head of R&D · O | ▽ Sale to issuer | 338,282 | — | — | -33.3% | — |
| Feb 21, 2026 | Munshi AmitD | ▽ Sale to issuer | 19,089 | — | — | -33.3% | — |
| Nov 21, 2025 | Sands Capital Life Sciences Pulse Fund II, L.P.10% | ▲ Buy | 2,068,965 | $1.45 | $3.0M | +18.9% | — |
Every $IKT filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Inhibikase Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $IKT feed.